Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (PBYI) Revenue
Annual & quarterly revenue history · segment & region breakdown
PBYI · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPuma Biotechnology, Inc. trailing twelve-month (TTM) revenue is $0.23B, a decrease of 0.91% year-over-year from $0.23B in FY2025.
Revenue trend
2025 – 2007 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.23B | -$0.00B | -0.91% |
| 2024-12-31 | $0.23B | -$0.01B | -2.19% |
| 2023-12-31 | $0.24B | +$0.01B | +3.34% |
| 2022-12-31 | $0.23B | -$0.03B | -9.92% |
| 2021-12-31 | $0.25B | +$0.03B | +12.46% |
| 2020-12-31 | $0.23B | -$0.05B | -17.32% |
| 2019-12-31 | $0.27B | +$0.02B | +8.47% |
| 2018-12-31 | $0.25B | +$0.22B | +806.14% |
| 2017-12-31 | $0.03B | +$0.03B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Puma Biotechnology, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Puma Biotechnology, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Puma Biotechnology, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PBYI revenue · 4 questionsPBYI's trailing twelve-month (TTM) revenue is $0.23B. That is a decrease of 0.91% year-over-year from $0.23B in FY2025.
▸ Source: FMP · Puma Biotechnology, Inc. SEC filings · GAAP · Puma Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026